EMA to make public side-effects in EudraVigilance database by end of 2011
This article was originally published in SRA
The European Medicines Agency by the end of 2011 plans to start granting public access to information in its EudraVigilance database on potential side-effects of certain human drugs1.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.